Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension

International Heart Journal

Volumn 51, Issue 4, 2010, Pages 272-276

  Hatano, Masaru ^a   Yao, Atsushi ^a   Shiga, Taro ^a   Kinugawa, Koichiro ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Imatinib mesylate; Platelet derived growth factor; Pulmonary arterial hypertension

Indexed keywords

BERAPROST; BOSENTAN; CARBON MONOXIDE; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; SILDENAFIL; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DOWN REGULATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EXERCISE; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCLERODERMA; SIDE EFFECT; UPREGULATION;

AGED; CARDIAC OUTPUT; COHORT STUDIES; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 77955813534     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.272     Document Type: Article

References (27)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436. (Review)
2. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
3. Hill NS, Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997; 83: 1209-1215.
4. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26: 194-201.
5. Li RC, Cindrova-Davies T, Skepper JN, Sellers LA. Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMPmediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ Res 2004; 94: 759-767.
6. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
7. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 115: 2691-2694. (Review)
8. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009; 34: 662-668.
9. Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
10. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
11. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153.
12. ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009; 98: 265-267.
13. García Hernández FJ, Castillo Palma MJ, González León R, Garrido Rasco R, Ocaña Medina C, Sánchez Román J. [Experience with imatinib to treat pulmonary arterial hypertension]. Arch Bronconeumol 2008; 44: 689-691. (Spanish)
14. Nakamura K, Akagi S, Matsubara H, et al. Imatinib inhibits proliferation and migration and induces apoptosis in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Circulation 2009; 120: S1136.
15. Yang J, Liu X, Nyland SB, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010; 115: 51-60.
16. Ranza E, Mazzini G, Facoetti A, Nano R. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 2010; 96: 349-357.
17. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 2005; 103: 1800-1809.
18. Handolias D, McArthur GA. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. Future Oncol 2008; 4: 211-217. (Review)
19. Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 2010; 29: 181-187.
20. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature. Leuk Res 2010; 34: 123-127. (Review)
21. Pou M, Saval N, Vera M, et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44: 1239-1241.
22. Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005; 39: 2136-2138.
23. François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis 2008; 51: 298-301.
24. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201: 925-935.
25. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171: 1279-1285.
26. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
27. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllärniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007; 33: 357-373.